Sygnis on the way to conquer the UK Life Sciences market

04/05/2015 - 2 minutes

Sygnis signed a distribution agreement with Cambridge Bioscience for the commercialization of its proprietary product portfolio in the UK and Ireland. This is a significant expansion of product roll-out into one of the most important life science markets in Europe.

Under the terms and conditions of the agreement, Cambridge Bioscience will promote, market, sell and support TruePrime products for primer-free WGA as well as SunScript thermostable reverse transcriptase kits for the translation of RNA into DNA to researchers in molecular biology in the UK and Ireland. Both are powerful tools addressing key challenges in next-generation sequencing (NGS) and single cell analysis (SCA).

TruePrime is based on Sygnis’ revolutionary novel multiple displacement amplification (MDA) technology addressing key challenges in NGS applications, increasingly demanded in fields such as oncology, pathology and clinical diagnostics.

On the other hand, the product line of Sygnis’ SunScript covers a series of kits based on novel proprietary engineered reverse transcriptase (RT) which today is one of the fastest and most thermostable enzymes commercially available.

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
ADVERTISEMENT
Do you want to remove this advert? Become a member!
ADVERTISEMENT
Do you want to remove this advert? Become a member!

Support Us

Become a Member